Form 4: Schrodinger CMO Sells Shares for Tax Obligations

Schrodinger's Chief Medical Officer, Margaret Dugan, sold 1,395 shares of common stock to cover tax liabilities from RSU vesting under a Rule 10b5-1 plan.

Summary

• Margaret Dugan, Chief Medical Officer of Schrodinger, Inc. (SDGR), reported the sale of 1,395 shares of common stock.
• The transaction occurred on October 16, 2025, at a price of $21.066 per share.
• The sale was executed pursuant to a durable automatic sale instruction under Rule 10b5-1, which was adopted by the reporting person on November 13, 2023.
• This was a broker-assisted sale specifically to satisfy withholding tax liability incurred upon the vesting of restricted stock units (RSUs).
• The sale does not represent a discretionary trade by Margaret Dugan.
• Following the transaction, Margaret Dugan beneficially owns 24,574 shares, which includes 20,000 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's explicitly stated as non-discretionary and for tax purposes under a pre-arranged plan, which mitigates any negative interpretation regarding management's confidence in the company.

Positives

• The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 plan, indicating it was not based on new material non-public information.
• The purpose of the sale was solely to cover tax liabilities from RSU vesting, a common and routine event for executives.

Negatives

• An insider sale, even for tax purposes, reduces the direct equity stake of a key executive in the company.

Management Comments

• The sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted on November 13, 2023.
• The sale represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ('RSUs').
• The sale does not represent a discretionary trade by the reporting person.

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as the sale is routine and non-discretionary, not signaling a change in management's outlook.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an insider to cover tax liabilities from RSU vesting, executed under a pre-arranged Rule 10b5-1 plan. It does not reflect a change in management's outlook or confidence in the company's future prospects, thus providing no new fundamental information to alter an existing investment thesis. Investors should 'hold' their position based solely on this filing.

Keywords

Schrodinger, SDGR, Insider Transaction, Form 4, Stock Sale, Rule 10b5-1, RSU Vesting, Tax Liability, Chief Medical Officer